van 't Verlaat J W, Croughs R J
Department of Neurosurgery, Rudolf Magnus Institute, Academic Hospital, Medical Faculty, Utrecht, The Netherlands.
Clin Endocrinol (Oxf). 1991 Mar;34(3):175-8. doi: 10.1111/j.1365-2265.1991.tb00289.x.
The present study describes the effect on plasma prolactin values and tumour size of bromocriptine withdrawal in 12 patients who had been treated for macroprolactinomas for a period of 3.5-7 (mean 4.9) years. Pretreatment plasma prolactin values ranged from 12,000 to 210,000 (mean: 66,000) mU/l. Immediately before bromocriptine withdrawal plasma prolactin values were in the normal range (less than 350 mU/l for men; less than 450 mU/l for women). Bromocriptine treatment was associated with tumour reduction in all cases. The following observations were made upon withdrawal of bromocriptine: (1) In 11 patients hyperprolactinaemia redeveloped although plasma prolactin levels remained below 600 mU/l in two of these patients during a follow-up period of 1 year. In the other nine patients bromocriptine treatment was reinstituted after 4-12 weeks. (2) Hyperprolactinaemia was associated with tumour reexpansion in one case and increased density of the tumour in two cases. (3) In one patient plasma prolactin remained undetectable during a follow-up period of 1 year and no tumour re-expansion was found. It is concluded that tumour regrowth is uncommon and of small extent after cessation of long-term bromocriptine treatment for macroprolactinomas.
本研究描述了12例接受大泌乳素瘤治疗3.5 - 7年（平均4.9年）的患者停用溴隐亭后对血浆泌乳素值和肿瘤大小的影响。治疗前血浆泌乳素值范围为12,000至210,000（平均：66,000）mU/l。在停用溴隐亭前，血浆泌乳素值处于正常范围（男性低于350 mU/l；女性低于450 mU/l）。所有病例中溴隐亭治疗均与肿瘤缩小相关。停用溴隐亭后有以下观察结果：（1）11例患者出现高泌乳素血症复发，尽管其中2例患者在1年的随访期内血浆泌乳素水平仍低于600 mU/l。在其他9例患者中，4 - 12周后重新开始溴隐亭治疗。（2）1例患者高泌乳素血症与肿瘤再次增大相关，2例患者肿瘤密度增加。（3）1例患者在1年的随访期内血浆泌乳素一直未检测到，且未发现肿瘤再次增大。结论是，长期溴隐亭治疗大泌乳素瘤停药后肿瘤再生不常见且程度较小。
Zotero 插件